This review synthesizes the emerging literature on sporozoite- and merozoite-specific IgA responses, examines how IgA arises in a “non-mucosal” infection like malaria, and explores vaccine platforms-oral, nasal, or prime-boost-that might harness IgA alongside IgG. This evidence concerns the gene CD79A and malaria.